IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • News
  • Cipla Limited - Mumbai. Related news

Cipla Limited - Mumbai. Related news

Cipla rebounds 13% from 52-week low on heavy volumes

Cipla rebounds 13% from 52-week low on heavy volumes

Shares of Cipla gained 5 per cent to Rs 442, thus bouncing back 13 per cent from its early morning low on the BSE on Friday as, according to analysts, the USFDA's inspection of Goa facility found no repeat or data integrity (DI) observations, so there is no chance of import alerts at the plant.

Cipla takes a knock on US FDA observations, overhang may continue

Cipla takes a knock on US FDA observations, overhang may continue

Investors in Cipla Ltd’s stock have been seeing its value erode to a 52-week low from its 52-week high levels, with the stock tumbling 36% in the past one year. News that the US Food and Drug Administration has made some further observations on Cipla’s Goa plant has further compounded the company’s woes. So far today, the stock has shed 4.1% in trade.

Cipla shareholders approve proposal to raise up to Rs 3,000 crore

Cipla shareholders approve proposal to raise up to Rs 3,000 crore

Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares.

Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares.

Cipla: India business reset and emerging market challenges crimp earnings expectations

Cipla: India business reset and emerging market challenges crimp earnings expectations

Shares of pharmaceutical major Cipla Ltd lost about 3% leading the losses in the NSE Nifty stocks at Wednesday noon trade. The deceleration in India business came as a negative surprise. Revenues in India, the largest business market for Cipla, dropped 12% as the company re-aligned its distribution channel.

Cipla clocks ₹447 crore profit in Q1

Cipla clocks ₹447 crore profit in Q1

NEW DELHI: Drug major Cipla on Wednesday reported a marginal rise in consolidated net profit at ₹447.15 crore for the quarter ended June 30, 2019.

The company had posted a net profit of ₹445.61 crore in the year-ago period, Cipla said in a filing to BSE.

Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug

Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug

Drug major Cipla Monday said its subsidiary InvaGen Pharmaceuticals has received final approval from the US health regulator for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses.

InvaGen has received approval from the the United States Food and Drug Administration (USFDA) for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, Cipla said in a regulatory filing.

Cipla Rating | Hold — Quarter results were ahead of expectations

Cipla Rating | Hold — Quarter results were ahead of expectations

Cipla reported Q4 results ahead of expectation led by gSensipar “at-risk” exclusivity launch. Ex of this, revenues were in line while margins were c100bps ahead of expectation. Management expects US business to grow in double digits in FY20 and base margins to improve though it did not quantify the level. Cipla trading at 20x FY21 PE, factors in the base business improvement. We retain Hold, noting the mixed execution over past 12m.

Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn

Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn

Cipla has entered into an agreement to acquire US-based specialty pharma company Avenue Therapeutics Inc for $215 mn or around Rs 15.6 bn. This is in line with Cipla's strategy of building a specialty drugs pipeline in the US.

Cipla's US subsidiary InvaGen Pharmaceuticals Inc will make the acquisition in two stages, the company said.

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

Drug major Cipla on Monday said it has received final approval from the US health regulator for Valganciclovir tablets used in the treatment of viral eye infection for AIDS patients.

Valganciclovir is used in the treatment of cytomegalovirus infection (serious viral eye infection of the retina) for AIDS patients and for prevention of cytomegalovirus (CMV) disease after organ transplant.

Cipla hits five-month low on weak outlook; down 12% in two days

Cipla hits five-month low on weak outlook; down 12% in two days

Shares of Cipla hit a five-month low of Rs 534, down 5% on Tuesday, extending its Monday’s 7% decline on the BSE, due to the weak outlook for the second half of the current fiscal (H2FY19). The pharmaceuticalmajor said there was pressure on the tender business, supply disruptions, commodity inflation and business impact from countries hit by sanctions.

  • Previous
  • 1
  • 2
  • Next

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
Illegal US entry means jail, deportation, visa ban: Embassy warns Indians
IndiaCatalog News
Adani Total Gas, Jio-bp tie up to offer petrol, diesel, CNG at fuel outlets
IndiaCatalog News
NSE offers $160 mn to settle dispute with Sebi, move ahead with IPO
IndiaCatalog News
India returns to space after 41 yrs, Shubhanshu Shukla lifts off on Axiom-4
IndiaCatalog News
ED raids in Gujarat, Maharashtra in cyber fraud probe over ₹100 cr scam

CORPORATE NEWS

Tata Motors
Tata Motors
Yes Bank
Yes Bank
Larsen & Toubro Limited
Larsen & Toubro Limited
National Association of Software & Service Companies (NASSCOM)
National Association of Software & Service Companies (NASSCOM)
Essar Oil Ltd.
Essar Oil Ltd.
Coal India Ltd
Coal India Ltd
Hyundai Motor India Ltd.
Hyundai Motor India Ltd.
Reliance Communications (RCOM)
Reliance Communications (RCOM)

PHOTO GALLERY

Hero HX250R
Hero HX250R
Parineeti Chopra
Parineeti Chopra
Narendra Modi Us Visit
Narendra Modi Us Visit
Rudhramadevi
Rudhramadevi
Mr.Perfect
Mr.Perfect
Irrfan Khan
Irrfan Khan
2017 IIFA Awards
2017 IIFA Awards
Salman Khan
Salman Khan
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com